Voices
Katy Beckermann: My ASCO26 GU Top 10 – Straight From the Program
Katy Beckermann/LinkedIn

Katy Beckermann: My ASCO26 GU Top 10 – Straight From the Program

Katy Beckermann, Medical Director of GU Clinical Research at Tennessee Oncology, shared a post on LinkedIn:

“My ASCO26 GU Top 10 — straight from the program.

Chicago is three weeks away. Here’s what I’ll be watching across prostate, bladder, and kidney cancer May 29–June 2:

  1. EV-302: 3.5-year follow-up (Abstract 4507) EV+P vs chemo in la/mUC. We know it works. Now we see how durable. The tail of this curve matters enormously for our patients.
  2. TALAPRO-3 LBA: Talazoparib + enzalutamide, HRR-mutated mCSPC Continued evidence to move up PARP inhibition in mCSPC. Strong rPFS, OS trend. The biomarker-selected mCSPC space is evolving fast.
  3. KEYNOTE-564 ctDNA (Abstract 4502) Can liquid biopsy tell us who actually benefits from adjuvant pembrolizumab in RCC? If this signal holds, it reshapes how we counsel patients after nephrectomy.
  4. A-DREAM: ADT interruption in exceptional responders, mHSPC A patient-centered question that’s long overdue. Can we safely de-escalate in the patients who respond beautifully to ADT? This is the kind of trial that changes conversations in clinic.
  5. ProstACT Global Phase 3, Part 1 (LBA5009) Safety and dosimetry of 177Lu-rosopatamab tetraxetan (PSMA-targeted rADC) in mCRPC. The next generation of radioligand therapy is entering Phase 3. June 1, Arie Crown.
  6. NEXUS-01: LY4052031 Nectin-4 ADC in mUC (Abstract 4508) EV has set the standard. Now we find out who comes next. First-in-human Phase 1 data for a new Nectin-4 ADC in mUC.
  7. AMBASSADOR HRQOL (Abstract 4513) Adjuvant pembro vs observation in MIUC, now with patient-reported outcomes. The efficacy case is made. This tells us whether patients actually experience the treatment well. Essential for informed consent.
  8. RADICAL: Radium-223 + cabozantinib in RCC with bone mets (Abstract 4500) A creative combination for a challenging clinical scenario. Bone-predominant RCC remains underserved and this Phase 2 has been on my radar.
  9. SHR-A2102 plus adebrelimab perioperative MIBC (Abstract 4506) A second nectin-4 ADC entering the perioperative bladder cancer space.
  10. RAMPART: Durvalumab monotherapy arm, adjuvant RCC Can PD-L1 blockade alone hold up after nephrectomy? The field has been waiting for this readout.

See you in Chicago.”

Katy Beckermann: My ASCO26 GU Top 10 - Straight From the Program

More posts featuring Katy Beckermann.

ASCO26 cancer Katy Beckermann OncoDaily Oncology